Results 121 to 130 of about 178,847 (197)

Toward Nano‐Nutritional Medicine: A Remotely Activated Trans‐Vaccenic Acid‐Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy

Advanced Science, EarlyView.
Eutectic mixtures from trans‐vaccenic acid (TVA) and stearic acid, which served as phase‐change material to encapsulate IR780, forming NIR‐responsive nanoparticles. IR780@TVA LNPs induce photothermal therapy and initiate adaptive anti‐tumor immunity.
Kang Liu, Yunlong Li, Hanmeng Liu, Peng Zhang, Mingjing Wang, Quanwei Sun, Wenshuo Yang, Zhengwei Song, Song Tan, Ye Yang, Peng She, Dengke Yin, Wei Shen   +12 more
wiley   +1 more source

Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression. [PDF]

Cancers (Basel)
Marković F, Bojić Z, Stjepanović M, Kontić M.   +3 more
europepmc   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

AK5 suppresses breast cancer progression and modulates anti-PD-L1 efficacy via the miR-182-5p/PD-L1 axis. [PDF]

iScience
Sun GS, Li YH, Li L, Fan LL, Yang H, Lu Q, Liu Z, Wang S, Peng JJ.   +8 more
europepmc   +1 more source

Targeting Lactate‐Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
Tumor‐derived lactate activates PSCs through MCT1‐mediated Vps34 lactylation and autophagy. These activated PSCs secrete CXCL9/10, upregulating PD‐1 on CD8+ T cells via the CXCR3/STAT3 axis to foster immunosuppression. Disrupting this metabolic crosstalk by targeting MCT1 effectively sensitizes pancreatic cancer to PD‐1 blockade, presenting a promising
Wenfeng Zhuo, Rong Hu, Yuhang Hu, Ping Hu, Shengbo Han, Guozheng Lv, Zhu Zeng, Yong Zhao, Yang Li, Yan Huang, Yingsong Zhao, Hongda Wang, Guangyu Zhao, Eryang Zhao, Gang Zhao   +14 more
wiley   +1 more source

From M7824 to SHR-1701: lessons for dual PD-L1/TGF-β targeting. [PDF]

J Immunother Cancer
Yi M, Li T, Wu K, Dai Z.
europepmc   +1 more source

Adaptive Coordination Engineering for Efficient and Robust H2 Release

Advanced Science, EarlyView.
β‐H elimination is a pivotal but challenging step in homogeneous formic acid dehydrogenation reactions due to strict hydride‐metal matching. By using a rationally designed Pd1Ag2 bimetallic system with adaptive Pd1‐Ag2/L2 coordination and formate bridges, it enables boosted formic acid dehydrogenation under ambient air (7.7 times higher than a Pd ...
Xiaolin Jiang, Xiaoyang Yan, Shenglong Jiang, Hongdan Zhu, Heng Wang, Xiaopeng Li, Xiaochun Zhou, Mingdong Zhou, Qian Peng   +8 more
wiley   +1 more source

Expression of YTHDF1 and YTHDF2 in lung squamous cell carcinoma and their correlation with PD-L1. [PDF]

J Thorac Dis
Cai L, Qu H, Feng K, He H, Wang F.
europepmc   +1 more source

Targeting DNGR‐1 with Fangchinoline Elevates Dendritic Cell Antigen Cross‐Presentation‐Mediated Antitumor Immunity in Melanoma

Advanced Science, EarlyView.
Fangchinoline is identified as a small‐molecule DNGR‐1 modulator that enhances dendritic‐cell cross‐presentation of tumor antigens. By engaging DNGR‐1 and activating Syk–Nox2 signaling, it promotes phagosomal ROS, antigen escape, MHC‐I presentation, and CD8+ T‐cell priming, thereby strengthening antitumor immunity and sensitizing tumors to PD‐1 ...
Yuan Liao, Zhenyang Ren, Jing Zhou, He Luo, Yuling Li, Dan Chen, Yuxiao Jiang, Canzhe Li, Mengyi Zheng, Anqi Li, Yao Wang, Yang Zhang, Dingye Wang, Yanjun Jiang, Jiangyong Gu, Biaoyan Du, Yafei Shi, Fang Liu, Jianyong Xiao, Kun Wang   +19 more
wiley   +1 more source

PD-L1 status on circulating tumor cells: a promising predictor in advanced lung cancer with PD-1/PD-L1 immunotherapies. [PDF]

Eur J Med Res
Wei X, Chen L, Yang Z, Zeng D, Tang D, Jiang J.   +5 more
europepmc   +1 more source